Objectives: In recent years workplace mobbing attracts notice in public and science. Victims of workplace mobbing frequently suffer from depressions, somatic symptoms, may develop alcoholism or other substance abuse disorders and show increased risk of suicidal behavior. The aim of this study was to calculate the number of patients with a workspace mobbing documentation and their diagnosis profile in general practices in Germany between 2003 and 2012 based on the data from a large epidemiological database. MethOds: This retrospective study analysed longitudinal routine care data collected by general practitioners in Germany (IMS® Disease Analyzer). Data from patients with notice as workplace mobbing (N= 2653) and without such notice (N= 2653) from 199 general medical practices in Germany (Disease Analyzer database; 01/2003 to 12/2012) were matched for age (41 ± 13 years), gender (male: 33%), health insurance (private: 5%) and retrospectively analyzed. Odds Ratio (OR; Logistic regression) for depression, anxiety, somatoform disorder, migraine and sleep disorder (follow-up: 3 years) were calculated. Results: In 2003, 24 (projected to national level: 2448) patients were documented as mobbing victims; this number continuously increased to 429 (projected to national level: 43758) in 2012. Shares of female patients and mean age have not significantly changed from 2003 till 2012. In workspace mobbing persons there was a increased risk of depression (OR: 4.11, p< 0.001), anxiety (OR: 2.76, p< 0.001), somatoform disorder (OR: 3.51, p< 0.001), migraine (OR: 1.41, p= 0.003) and sleep disorder (OR: 2.32, p< 0.001). cOnclusiOns: This retrospective database analysis showed that experience of workspace mobbing was associated with increased prevalence of psychiatric and neurological problems. Further research is required to understand this complex issue.

This analysis underlines an association between the initiation of rebate contracts and a negative impact on the compliance of breast cancer patients on an adjuvant hormonal treatment The impact of rebate contracts on the health of patients and the health care costs should be evaluated in further therapeutic fields through additional research projects. *both authors contributed equally to the manuscript.

Diabetes is one of the most common chronic diseases with an estimated worldwide prevalence of around 8.3%. 1 There are around 60 million people with diabetes in Europe (10.3% of men and 9.6% of women aged 25 years and over). 2 Type 2 diabetes mellitus (T2DM) is present in 90% of diabetic patients. 3 T2DM has a serious impact on health and the economy in Europe. This disease is known to be associated with several other disorders, such as retinopathy, 4 nephropathy, 5 neuropathy, 6 atherosclerosis, 7 cardiovascular disease, 8 stroke, 9 and cerebrovascular disease. 10 Recently, a meta-analysis of 35 studies conducted by Nwaneri and colleagues has shown that T2DM and its complications, in particular stroke, cause a 2-fold increase in mortality rates. 11 Numerous drugs are available for the treatment of patients with T2DM. Metformin and sulfonylureas have been used for decades, either as monotherapies or as part of combination therapies. 12-14 Since the mid-2000s, several new drugs presenting fewer side effects than metformin and sulfonylureas have emerged for T2DM treatment: dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, and sodium-glucose cotransporter-2 (SGLT2) inhibitors. Their 607860D STXXX10.

No abstract

No abstract